Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
OPHT's Cash-to-Debt is ranked higher than
76% of the 983 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. OPHT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OPHT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset -0.55
OPHT's Equity-to-Asset is ranked lower than
96% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPHT: -0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
OPHT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.55  Med: 0.14 Max: 0.36
Current: -0.55
-0.55
0.36
Interest Coverage No Debt
OPHT's Interest Coverage is ranked higher than
69% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPHT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPHT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -5.28
Beneish M-Score: -5.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -548.97
OPHT's Operating Margin % is ranked lower than
70% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. OPHT: -548.97 )
Ranked among companies with meaningful Operating Margin % only.
OPHT' s Operating Margin % Range Over the Past 10 Years
Min: -548.97  Med: -239.84 Max: -195.14
Current: -548.97
-548.97
-195.14
Net Margin % -543.39
OPHT's Net Margin % is ranked lower than
71% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. OPHT: -543.39 )
Ranked among companies with meaningful Net Margin % only.
OPHT' s Net Margin % Range Over the Past 10 Years
Min: -543.39  Med: -283.02 Max: -205.26
Current: -543.39
-543.39
-205.26
ROA % -59.84
OPHT's ROA % is ranked lower than
73% of the 992 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. OPHT: -59.84 )
Ranked among companies with meaningful ROA % only.
OPHT' s ROA % Range Over the Past 10 Years
Min: -241.11  Med: -49.53 Max: -23.27
Current: -59.84
-241.11
-23.27
ROC (Joel Greenblatt) % -2744.62
OPHT's ROC (Joel Greenblatt) % is ranked lower than
74% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: -369.38 vs. OPHT: -2744.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPHT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -26895.89  Med: -12055.47 Max: -2744.62
Current: -2744.62
-26895.89
-2744.62
3-Year EBITDA Growth Rate 1.40
OPHT's 3-Year EBITDA Growth Rate is ranked higher than
51% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. OPHT: 1.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OPHT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: -27.7 Max: 1.4
Current: 1.4
-44.4
1.4
3-Year EPS without NRI Growth Rate -4.90
OPHT's 3-Year EPS without NRI Growth Rate is ranked lower than
54% of the 553 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OPHT: -4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPHT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.3  Med: -41 Max: -4.9
Current: -4.9
-42.3
-4.9
GuruFocus has detected 3 Warning Signs with Ophthotech Corp $OPHT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPHT's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:CYDY, OTCPK:MCUJF, NAS:PTI, NAS:AGTC, NAS:AXSM, OTCPK:IPIX, NAS:ORMP, OTCPK:DTHR, NAS:ZFGN, NAS:AFMD, NAS:CYTR, NAS:CBMG, AMEX:RNN, NAS:INFI, NAS:LIFE, NAS:AVEO, NAS:GLMD, NAS:VCEL, NAS:BCLI, NAS:NTEC » details
Traded in other countries:O2T.Germany,
Headquarter Location:USA
Ophthotech Corp is a biopharmaceutical company. The Company is engaged in the development of novel therapeutics to treat diseases of the back of the eye, developing therapeutics for age-related muscular degeneration.

Top Ranked Articles about Ophthotech Corp

INVESTOR COMPLAINT: Levi & Korsinsky, LLP Reminds Investors of Ophthotech Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017

NEW YORK, March 08, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (“Ophthotech”) (NASDAQ:OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al. (Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information go to: http://zlk.9nl.com/ophthotech or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that, throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices. On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29. Take Action: if you suffered a loss in Ophthotech you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Ophthotech Corporation and Certain Officers – OPHT

NEW YORK, March 06, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ophthotech Corporation (“Ophthotech” or the “Company”) ( OPHT) and certain of its officers.   The class action, filed in United States District Court, Southern District of New York, is on behalf of a class consisting of investors who purchased or otherwise acquired Caterpillar securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Ophthotech securities between May 11, 2015 and December 12, 2016, both dates inclusive, you have until March 13, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.  [Click here to join this class action] Ophthotech is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). AMD is a disorder of the central portion of the retina, which is responsible for central vision and color perception. The Company’s most advanced product candidate during the Class Period was Fovista, a PDGF aptamer. As a PDGF aptamer, Fovista was designed to block proteins that bind to cells on the outer lining of blood vessels. Fovista was to be administered in combination with VEGF agents, a standard of care for the treatment of wet AMD. Similar to PDGF aptamers, antiVEGF agents are designed to block proteins that bind to cells on the inner lining of blood vessels. By combining PDGF aptamers (like Fovista) and anti-VEGF agents, proteins on both the inner and outer lining of blood vessels which cause growth and leakage would be blocked, promoting blood vessel regression and reducing scarring. Prior to the Class Period, the Company had completed phase 1 and phase 2 studies evaluating Fovista in combination with the anti-VEGF Lucentis (ranibizumab), and had initiated multiple extension trials to evaluate Fovista in combination with other commercially available anti-VEGF agents. For instance, Ophthotech announced the results of its phase 2b clinical study of Fovista in combination with Lucentis on June 13, 2012, in a press release entitled “Anti-PDGF (1.5 mg) Combination Therapy Resulted in Additional 62% Increase in Visual Outcome Compared to Lucentis® Monotherapy.” The Phase 2b study was a prospective, randomized, controlled clinical trial of 449 patients with wet AMD, and a primary endpoint of mean vision gain. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The Complaint further alleges that these statements caused the Company stock to trade at artificially inflated prices. On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...
OPHTHOTECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ophthotech Corporation – (OPHT)

NEW ORLEANS, March 03, 2017 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Ophthotech Corporation (NASDAQ:OPHT), if they purchased the Company’s shares between May 11, 2015 and December 12, 2016, inclusive (the “Class Period”).  The action is pending in United States District Court for the Southern District of New York. 
What You May Do If you purchased shares of Ophthotech and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 13, 2017. About the Lawsuit Ophthotech and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  The complaint alleges that Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint. On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis. On this news, the price of Ophthotech’s shares plummeted. About Kahn Swick & Foti, LLC KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447

Read more...
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Ophthotech Corporation (OPHT) To Contact The Firm

STEVENSON, Md., March 03, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Ophthotech Corporation (NASDAQ:OPHT) (“Ophthotech” or the “Company”) common stock during the period between May 11, 2015 and December 12, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Ophthotech common stock during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Ophthotech’s phase 3 clinical trials of Fovista would fail to achieve their primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone because Lucentis’ gain of vision in the Phase 2b clinical trial was not representative of Lucentis’ actual performance, Fovista’s gain of vision in the Phase 2b clinical trial was therefore biased, and Ophthotech inappropriately relied on its Phase 2b results as a means of touting its Phase 3 clinical trial of Fovista. According to the complaint, following a December 12, 2016 announcement that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statically significant improvement over patients only receiving Lucentis, the value of Ophthotech shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in Ophthotech common stock purchased on or after May 11, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
Steven Cohen Adds to Fairmount Santrol, Ophthotech Guru increases his positions in energy company, biopharmaceutical company
Steven Cohen (Trades, Portfolio), founder and CEO of Point72 Asset Management, increased his position in two holdings recently. He increased his holding in Fairmount Santrol Holdings Inc. (NYSE:FMSA) by 21.2% on Dec. 7 and increased his position in Ophthotech Corp. (NASDAQ:OPHT) by 128.9% on Dec. 8. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 1.64
OPHT's Forward PE Ratio is ranked higher than
97% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 21.65 vs. OPHT: 1.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PS Ratio 2.84
OPHT's PS Ratio is ranked higher than
83% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.91 vs. OPHT: 2.84 )
Ranked among companies with meaningful PS Ratio only.
OPHT' s PS Ratio Range Over the Past 10 Years
Min: 2.25  Med: 32.93 Max: 70.25
Current: 2.84
2.25
70.25
EV-to-EBIT 0.60
OPHT's EV-to-EBIT is ranked higher than
91% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 22.66 vs. OPHT: 0.60 )
Ranked among companies with meaningful EV-to-EBIT only.
OPHT' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.3  Med: -11.55 Max: 0.7
Current: 0.6
-37.3
0.7
EV-to-EBITDA 0.61
OPHT's EV-to-EBITDA is ranked higher than
92% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.28 vs. OPHT: 0.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPHT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.7  Med: -11.65 Max: 0.7
Current: 0.61
-37.7
0.7
Current Ratio 5.45
OPHT's Current Ratio is ranked higher than
60% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OPHT: 5.45 )
Ranked among companies with meaningful Current Ratio only.
OPHT' s Current Ratio Range Over the Past 10 Years
Min: 0.34  Med: 12.5 Max: 40.94
Current: 5.45
0.34
40.94
Quick Ratio 5.45
OPHT's Quick Ratio is ranked higher than
61% of the 976 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. OPHT: 5.45 )
Ranked among companies with meaningful Quick Ratio only.
OPHT' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 12.5 Max: 40.94
Current: 5.45
0.34
40.94
Days Sales Outstanding 34.97
OPHT's Days Sales Outstanding is ranked higher than
75% of the 627 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. OPHT: 34.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPHT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.49  Med: 25.32 Max: 34.97
Current: 34.97
8.49
34.97

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
OPHT's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. OPHT: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPHT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -190  Med: -189.4 Max: -4.4
Current: -4.4
-190
-4.4

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.09
OPHT's Price-to-Median-PS-Value is ranked higher than
97% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. OPHT: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPHT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.98 Max: 1.76
Current: 0.09
0.08
1.76
Earnings Yield (Greenblatt) % 165.71
OPHT's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.87 vs. OPHT: 165.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPHT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -21.3  Med: -6.8 Max: 216.7
Current: 165.71
-21.3
216.7

More Statistics

Revenue (TTM) (Mil) $36.85
EPS (TTM) $ -5.62
Beta1.45
Short Percentage of Float14.62%
52-Week Range $2.24 - 65.96
Shares Outstanding (Mil)35.85

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) 1.75 -1.50 -1.35
EPS without NRI ($) 1.75 -1.50 -1.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OPHT

Headlines

Articles On GuruFocus.com
INVESTOR COMPLAINT: Levi & Korsinsky, LLP Reminds Investors of Ophthotech Corporation of a Class Act Mar 08 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Ophthotech Co Mar 06 2017 
OPHTHOTECH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS IN Mar 04 2017 
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsui Mar 03 2017 
Steven Cohen Adds to Fairmount Santrol, Ophthotech Dec 16 2016 
Largest Insiders' Trades of the Week May 27 2016 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Weekly 3-Year Low Highlight: VIV, CNHI, WTW, OPHT Nov 17 2013 
Insiders Are Buying Ophthotech Oct 08 2013 

More From Other Websites
Why Is Ophthotech (OPHT) Down 13.7% Since the Last Earnings Report? Jun 06 2017
Edited Transcript of OPHT earnings conference call or presentation 3-May-17 12:00pm GMT May 18 2017
Newman Ferrara LLP Announces Corporate Governance Investigation of Ophthotech Corp. - OPHT May 15 2017
Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss May 04 2017
Ophthotech reports 1Q loss May 03 2017
Ophthotech Reports First Quarter 2017 Financial and Operating Results May 03 2017
Investor Network: Ophthotech Corp. to Host Earnings Call May 03 2017
ETFs with exposure to Ophthotech Corp. : May 1, 2017 May 01 2017
Ophthotech Corporation to Report First Quarter 2017 Financial Results and Host Conference Call on... Apr 26 2017
Ophthotech Announces Leadership Transition Effective July 1, 2017 Apr 24 2017
ETFs with exposure to Ophthotech Corp. : April 7, 2017 Apr 07 2017
Ophthotech (OPHT) Down 2.9% Since Earnings Report: Can It Rebound? Mar 31 2017
ETFs with exposure to Ophthotech Corp. : March 27, 2017 Mar 27 2017
Ophthotech Corp. :OPHT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Ophthotech Corp. :OPHT-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
OPHTHOTECH 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General... Mar 10 2017
EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech Corporation... Mar 09 2017
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech... Mar 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}